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ttp://dx.doi.org/10.1016/j.ajpath.2012.09.003Neovascular diseases of the eye are the most common causes of blindness worldwide. The mechanisms
underlying pathological neovascularization in the retina remain incompletely understood. PGC-1a is
a transcriptional coactivator that plays a central role in the regulation of cellular metabolism. In
skeletal muscle, PGC-1a induces VEGFA expression and powerfully promotes angiogenesis, suggesting
a similar role in other tissues. This study investigates the role of PGC-1a during normal and patho-
logical vascularization in the retina. We show that PGC-1a induces the expression of VEGFA in
numerous retinal cells, and that PGC-1a expression is strongly induced during postnatal retinal
development, coincident with VEGFA expression and angiogenesis. PGC-1a/ mice have a significant
reduction of early retinal vascular outgrowth, and reduced density of capillaries and number of
main arteries and veins as adults. In the oxygen-induced retinopathy model of retinopathy of
prematurity, PGC-1a expression is dramatically induced in the inner nuclear layer of the retina, sug-
gesting that PGC-1a drives pathological neovascularization. In support of this, PGC-1a/ mice
subjected to oxygen-induced retinopathy had decreased expression of VEGFA and were protected
against pathological neovascularization. These results demonstrate that PGC-1a regulates VEGFA in the
retina and is required for normal vessel development and for pathological neovascularization. The data
highlight PGC-1a as a novel target in the treatment of neovascular diseases of the eye. (Am J Pathol
2013, 182: 255e265; http://dx.doi.org/10.1016/j.ajpath.2012.09.003)Supported by the March of Dimes (Z.A.), the Harvard Catalyst j The
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M.S.-G. and A.J. contributed equally to this work.The mature retina is a highly metabolic neural tissue with the
highest oxygen consumption per unit weight of any human
tissue.1 In most mammals, the adult retina is vascularized by
two independent circulatory systems: the retinal vessels that
supply the inner part of the retina, and the choroidal vessels
that supply the deeper section of the retina.2 Retinal blood
vessels normally are quiescent with respect to growth.3
However, in a variety of retinal pathologies, such as prolif-
erative diabetic retinopathy, venous occlusion, age-related
macular degeneration, and retinopathy of prematurity
(ROP), abnormal angiogenic growth of vessels into the
retinal tissue and/or the vitreous leads to serious vision loss.
ROP, the leading cause of blindness in premature and very-
low-birth-weight infants,4 is caused by disorganized retinal
vascular growth.5 Vascularization of the retina in humans is
normally complete and stabilized at term. By contrast, the
immature vessels of preterm infants placed in hyperoxic
incubators regress in the face of increased oxygen tension
(vaso-obliterative phase).6 Once returned to normoxia, thestigative Pathology.
.insufﬁciently perfused retina becomes ischemic, and
dramatically induces vascular endothelial growth factor A
(VEGFA) and abnormal vessel growth (vaso-proliferative
phase). Current approaches to the treatment of ROP only
reduce the incidence of blindness by 25%, and are destructive
to the retina.7 More recent efforts with anti-VEGF therapy
have yielded promising results, underscoring the importance
of VEGFA in this disease.8 Understanding the pathophysi-
ology of ROP, and identifying potentially targetable
Saint-Geniez et alpathways that regulate retinal VEGFA and angiogenesis, is
therefore of great interest.
The transcription factor hypoxia inducible factor-1a (HIF-
1a) has long been proposed as the main force driving retinal
vascularization in both normal and pathological conditions.9
However, this concept has recently been challenged. For
example, using genetically modiﬁed mice in which the
VEGFA promoter lacks the HIF-responsive element and
therefore is unable to produce VEGFA in response to HIF-1a,
Vinores et al10 showed that HIF-1aedependent VEGFA
regulation was surprisingly not required for normal retinal
vascularization. We recently described in skeletal muscle
a novel and HIF-independent pathway that powerfully regu-
lates angiogenesis, involving the transcriptional coactivator
PPARg-coactivator-1a (PPARGC1A; alias PGC-1a).11
PGC-1a is a powerful regulator of mitochondria and oxida-
tive metabolism in numerous tissues (reviewed in Kelly and
Scarpulla,12 Lin et al,13 Handschin and Spiegelman,14 and
Arany15). In addition, we recently showed that PGC-1a also
regulates an angiogenic program, including VEGFA and
other angiogenic factors, in cultured muscle cells and skeletal
muscle in vivo.11 Transgenic expression of PGC-1a in skel-
etalmuscle dramatically increasedmicrovascular density, and
was protective in a model of skeletal muscle ischemia. PGC-
1a, a major regulator of mitochondrial function, thus also
controls a novel and powerful angiogenic pathway in skeletal
muscle, suggesting that it may also do so in other tissues.
Despite the fact that the retina is one of the most metabol-
ically active and vascularized tissues in the body, little is
known about the role of PGC-1a in the eye. Only one report
recently implicated PGC-1a in the survival of photoreceptor
cells to light-induced damage.16 The identiﬁcation of PGC-1a
as a novel regulator of angiogenesis, and its important role in
metabolism, led us to suspect that it may play a role in retinal
vascular development and in ROP. We show here that PGC-
1a is expressed in the retina, that its expression rises
dramatically within the developing retina, and that PGC-1a
can induce VEGFA in retinal cells. Moreover, PGC-1a/
mice have delayed retinal vasculature outgrowth and are
protected from pathological neovascularization in a model of
proliferative retinopathy similar to ROP.
Materials and Methods
Animals
All animal experiments were approved by the Schepens Eye
Research Institutional Animal Care and Use Committee.
PGC-1aedeﬁcient mice have been previously described.17
Oxygen-induced retinopathy (OIR) was induced by placing
postnatal day (P) 7 mice in 75 2% oxygen for 5 consecutive
days, as previously described.18
Cells and Reagents
The human Müller cell line, MIO-M1 (a gift from G. Astrid
Limb, Institute of Ophthalmology and Moorﬁelds Eye256Hospital, London, UK), and the murine cone cell line,
661W (a gift from Dr. Al-Ubaidi, Department of Cell
Biology, University of Oklahoma Health Sciences Center)
were maintained in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) (Invitrogen/Gibco, Carlsbad, CA) supplemented
with 100 IU/mL penicillin, 100 mg/mL streptomycin (all
from Gibco), and 10% heat-inactivated fetal bovine serum
(Atlanta Biologicals, Lawrenceville, GA). The rat ganglion
cell line, RGC-5, was maintained in DMEM with 1.0 g/L
glucose (Invitrogen/Gibco) with 100 IU/mL penicillin,
100 mg/mL streptomycin (all from Gibco), and 10% heat-
inactivated fetal bovine serum (Atlanta Biologicals). ARPE-
19 cells (American Type Culture Collection, Manassas, VA)
were maintained in DMEM/F12 medium (Lonza, Basel,
Switzerland), 100 IU/mL penicillin, 100 mg/mL strepto-
mycin (all from Gibco), and 10% heat-inactivated fetal
bovine serum (Atlanta Biologicals). RGC5 differentiation
was induced by 1 mmol/L staurosporine in DMEM (without
serum or antibiotics) for 1 hour at 37C. All cultures were
maintained in a humidiﬁed atmosphere of 95% air and 5%
CO2 at 37C. Retrovirus and adenoviruses overexpressing
PGC-1a have been described.19,20 For PGC-1a knock-
down, MIO-M1s were infected with lentivirus carrying
human PGC-1a short hairpin (shPGC-1a) plasmid or green
ﬂuorescent protein (GFP) short hairpin (shGFP) plasmid
(obtained from the RNAi Consortium at the Broad Institute
of Harvard and MIT) and selected for puromycin resistance.
PGC-1a expression was conﬁrmed by quantitative PCR
(qPCR) of the PGC-1a gene as well as its downstream
target genes. PGC-1a expression at protein level was
measured by Western blotting. MIO-M1 cells were starved
in DMEM with 0.5% FBS overnight and then kept in
normoxia or hypoxia (complete deprivation of oxygen) for
24 hours before harvesting for qPCR or enzyme-linked
immunosorbent assay for VEGFA expression levels.
VEGFA enzyme-linked immunosorbent assay was per-
formed on conditioned media using the Human VEGF
Quantikine kit (R&D Systems, Minneapolis, MN) according
to the manufacturer’s instructions.
qPCR
Total RNA was isolated from tissue and cells using RNA-
Bee solution (Iso-Tex Diagnostics, Friendswood, TX) or the
TurboCapture 384 mRNA Kit (Qiagen, Valencia, CA).
RNA was reverse-transcribed using iScript (Bio-Rad
Laboratories, Hercules, CA) or the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster City,
CA). qPCR reactions were performed using the SYBR
Green Master Mix and the ABI Prism 9700 Sequence
Detection System (Applied Biosystems) or the CFX384
Real-Time System (Bio-Rad) according to the manufac-
turers’ instructions. To ensure accurate gene quantiﬁcation,
the PCR data were normalized to the mean of multiple
internal control genes (HRPT, B2M, ACTB, and TBP),21 and
gene expression was calculated according to the DDCTajp.amjpathol.org - The American Journal of Pathology
PGC-1a and Retinal Angiogenesismethod. The list of genes investigated by qPCR are listed in
Table 1, and the respective primers used are listed in
Table 2.
Laser-Capture Microdissection
Enucleated eyes from P17 animals exposed to the OIR
model and from controls were ﬂash frozen in optimal
cutting temperature compound under RNase-free condi-
tions. Sixteen-micron sections were obtained using a cryo-
stat (Leica 3050S; Leica Microsystems, Wetzlar, Germany),
mounted on polyethylene terephthalate slides (Leica
Microsystems), and then stained immediately or stored at
80C. Before laser microdissection, sections were ﬁxed
and dehydrated in 50% then 75% ethanol, and washed in
nuclease-free water (Ambion, Foster City, CA). Sections
were brieﬂy stained for 20 seconds in 0.1% toluidine blue
dye (Sigma-Aldrich, St. Louis, MO), rinsed in nuclease-free
water and destained in 75% ethanol. The outer nuclear layer
(ONL), inner nuclear layer (INL), and ganglion cell layer
(GCL) were captured using a Laser Microdissection
Microscope (Model AS LMD; Leica Microsystems). Total
RNA was isolated using an RNeasy Micro kit (Qiagen) and
quantiﬁed by Nanodrop spectrophotometry (Thermo Fisher
Scientiﬁc, Waltham, MA).
Western Blot
Cell lysates were loaded onto a NuPAGE Novex 4% to 12%
Bis-Tris Gel (Invitrogen), normalized for protein content.
After being separated by size, proteins were transferred
to an Immobilon membrane (Millipore, Billerica, MA).
The membrane was blocked with 3% milk in TBST buffer
for 1 hour at room temperature and incubated with an
antiePGC-1a antibody (ST1202, 1:1000; Calbiochem/
Millipore) in 3% milk in TBST buffer overnight at 4C. The
membrane was then incubated with secondary antibody
(1:10,000; Jackson ImmunoResearch Laboratories, WestTable 1 List of Genes Studied
Symbol Name
ACTB Beta-actin
TBP TATA box binding protein
HPRT1 Hypoxanthine phosphoribosyl-transferase 1
B2M Beta-2-microglobulin
COX5B Cytochrome c oxidase subunit Vb
ATP5O ATP synthase, Hþ transporting,
mitochondrial F1 complex, O subunit
PPARGC1A
(alias PGC-1a)
Peroxisome proliferator-activated receptor
gamma, coactivator 1 alpha
CYCS Cytochrome c, somatic
ACADM
(alias MCAD)
Medium chain acyl CoA dehydrogenase
VEGFA Vascular endothelial growth factor A
PDGFB Platelet-derived growth factor beta polypeptide
ANGPT1 Angiopoietin 1
ANGPT2 Angiopoietin 2
The American Journal of Pathology - ajp.amjpathol.orgGrove, PA) in 3% milk in TBST buffer for 1 hour at room
temperature.
Spectral-Domain Optical Coherence Tomography
Imaging and ONL Thickness Quantification
Images centered on the optic nerve head were acquired on
live anesthetized animals with spectral-domain optical
coherence tomography (SD-OCT) (Bioptigen, Research
Triangle Park, NC). Volume analysis was performed using
100 horizontal, raster, and consecutive B-scan lines, each
one composed of 1200 A-scans. The volume size was 1.6 
1.6 mm. ONL thickness was measured using Photoshop
CS4 (Adobe Systems, San Jose, CA) on cross-sectional
areas every 100 mm from the optic nerve on each side.
Histology and Immunohistochemistry
For histology, whole eyes were ﬁxed with 10% formalin and
prepared for parafﬁn embedding and sectioning. Sagittal
sections were stained with hematoxylin and eosin. Whole
retinas were dissected and immunostained as previously
described.22 Brieﬂy, whole retinas were blocked 2 hours
with 1% bovine serum albumin in PBS containing
0.1 mmol/L CaCl2, and 0.1 mmol/L MgCl2 and incubated
overnight with the appropriate antibody: Alexa 488elabeled
(I21411; Invitrogen) or Alexa 594elabeled isolectin IB4
(I21413; Invitrogen), anti-smooth muscle actin (C6198;
Sigma-Aldrich) or anti-collagen IV (ab19808; Abcam).
Primary antibodies were visualized using Cy5- or Cy3-
conjugated secondary antibodies (Jackson ImmunoR-
esearch Laboratories). Vascular outgrowth, avascular area,
and neovascular area were measured on ﬂat-mounted retinas
using Photoshop CS4 as previously described.23 Vascular
density at P4 was quantiﬁed on six ﬁelds/retina with each
ﬁeld representing 0.057 mm2 located midway between the
optic disk and the periphery and away from any main
arteries or veins.
In Situ Hybridization
PGC-1a probe was obtained by subcloning a 661-bp region
of the mouse PGC-1a cDNA (nucleotides 646 to 1307) into
the pBluescript KSþ vector (Stratagene/Agilent Technolo-
gies, Santa Clara, CA) and transcribed in vitro to produce
antisense and sense riboprobes labeled with digoxigenin.
Flat-mounted retinas were hybridized and stained following
the method previously described,24 with some modiﬁca-
tions. Samples were prehybridized at 65C for 6 hours
and hybridized at 60C for 12 hours. The detection was
performed with alkaline phosphataseecoupled anti-
digoxigenin antibodies (11093274910, 1/2000; Roche
Applied Science, Indianapolis, IN) overnight at 4C. After
washing, the chromogenic reaction was obtained with NBT/
BCIP substrate (Promega, Madison, WI). After color
development, the ﬂat-mounted retinas were ﬁxed in 4%257
Table 2 Primer Sequences Utilized for qPCR Analysis
Species Symbol Forward primer Reverse primer
Mouse Actb 50-CCCTGTATGCCTCTGGTCGTACCAC-30 50-GCCAGCCAGGTCCAGACGCAGGATG-30
Mouse Tbp 50-CCCTATCACTCCTGCCACACCAGC-30 50-GTGCAATGGTCTTTAGGTCAAGTTTACAGCC-30
Mouse Hprt 50-GTTAAGCAGTACAGCCCCAAA-30 50-AGGGCATATCCAACAACAAACTT-30
Mouse B2m 50-GTGGCCCTTAGCTGTGCTCG-30 50-ACCTGAATGCTGGATAGCCTC-30
Mouse Cox5b 50-GCTGCATCTGTGAAGAGGACAAC-30 50-CAGCTTGTAATGGGTTCCACAGT-30
Mouse Atp5o 50-AGGCCCTTTGCCAAGCTT-30 50-TTCTCCTTAGATGCAGCAGAGTACA-30
Mouse PGC-1a* 50-GCTGCATGGTTCTGAGTGCTAAG-30 50-TCTGGTACCCAAGGCAGCC-30
Mouse Cycs 50-GCAAGCATAAGACTGGACCAAA-30 50-TTGTTGGCATCTGTGTAAGAGAATC-30
Mouse Acadm 50-CAGCTAGCCACTGACGCCGTGCAG-30 50-GCTCACGAGCTATGATCAGCCTCTG-30
Mouse Vegfa 50-GAGGATGTCCTCACTCGGAT-30 50-TCTCAGACCACACTGAAGCC-30
Mouse Pdgfb 50-CGAGCCAAGACGCCTCAAGCTCGG-30 50-GGCCGCCTTGTCATGGGTGTGC-30
Mouse Angpt1 50-GAAAATATGAAGTCGGAGATGGCCC-30 50-CCTATCTCAAGCATGGTGGCCGTGTG-30
Mouse Angpt2 50-GCCACGGTCAACAACTCGCTCC-30 50-GCAACCGAGCTCTTGGAGTTGG-30
Human HPRT1 50-TGGACAGGACTGAACGTCTTG-30 50-AGGGCATATCCAACAACAAACTT-30
Human ACTB 50-GAGCGCGGCTACAGCTT-30 50-TCCTTAATGTCACGCACGATTT-30
Human COX5B 50-GGAAGACCCTAATTTAGTCCCCT-30 50-CCAGCTTGTAATGGGCTCCAC-30
Human PGC-1a 50-GCTTTCTGGGTGGACTCAAGT-30 50-TCTAGTGTCTCTGTGAGGACTG-30
Human VEGFA 50-CAACATCACCATGCAGATTATGC-30 50-CCCACAGGGATTTTCTTGTCTT-30
*PPARGC1A is the official gene symbol for PGC-1a (Ppargc1a in mouse)
Saint-Geniez et alparaformaldehyde, embedded in optimal cutting temperature
compound, and cryosectioned.
Statistical Analysis
Values are expressed as mean  SEM (unless speciﬁed
otherwise), and statistical analysis was performed using an
unpaired Student’s t-test.
Results
PGC-1a Is Strongly Expressed in Retinal Cells, and Is
Dramatically Induced during Retinal Development
PGC-1a is a potent regulator of metabolism and angio-
genesis in multiple tissues. The role of PGC-1a in the retina
has not been investigated. To begin to investigate its role,
the relative expression of PGC-1a in murine retinas was
measured. Total RNA was prepared from various murine
tissues, including retina, heart, and liver, using the Trizol
method. The RNA was then reverse transcribed, and the
expression of PGC-1a was measured by qPCR. As shown
in Figure 1A, PGC-1a is well expressed in the adult retina,
at levels comparable to a number of tissues in which PGC-
1a is well known to play important roles. This pattern of
expression matches that observed in moderate-throughput
microarray analyses publicly available, including from
BioGPS, where expression of PGC-1a is strongly detected
in a number of retinal components, including retinal
pigment epithelium, iris, and ciliary body (Supplemental
Figure S1).
Next, the expression of PGC-1a during postnatal devel-
opment in the retina was measured. As shown in Figure 1B,
PGC-1a expression rises more than 20-fold during retinal
development, beginning as early as P5 and peaking by P15258to P17. PGC-1a induction coincides with the rising
expression of genes involved in mitochondrial function,
well-known targets of PGC-1a (CYCS, MCAD; Figure 1C),
as well as a number of angiogenic genes such as VEGFA,
PDGFB, and ANG2 (Figure 1D). Interestingly, although
expression of proangiogenic factors reaches its peak at P7,
the time of maximal vascular outgrowth, and then declines
during the later stages of retinal development (P12 to P15)
to allow for vascular plexus remodeling,25 PGC-1a
expression remains high, suggesting that sustained expres-
sion of PGC-1a may be required for retinal homeostasis
beyond P12. We next used in situ hybridization to determine
the PGC-1a expression pattern in the retina. At P7.5,
PGC-1a expression is seen prominently in the ONL that
contains the differentiating photoreceptors (PR), as well as
more weakly in the INL and GCL (Figure 1E). In the adult
retina, PGC-1a expression was more evenly distributed
across all of the cellular layers (Figure 1E). PGC-1a is thus
well expressed in the retina, and is strongly induced during
early postnatal retinal development, coincident with physi-
ological vascularization of the retina.
PGC-1a Regulates VEGFA Expression in Multiple
Retinal Cell Types
The data above and our studies in skeletal muscle11,26 sug-
gested that PGC-1amight regulate VEGFA and angiogenesis
in the retina. To test this, a number of retinal cell lines were
infected with adenovirus expressing PGC-1a, versus GFP
control virus, andVEGFAexpressionwasmeasured by qPCR
48 hours later. As shown in Figure 2, AeD, delivery of PGC-
1a by adenoviral infection efﬁciently induced the expression
ofCox5b, a well-establishedmitochondrial target of PGC-1a,
in a number of retinal cells, including Müller (glial) cells
(MIO-M1) (Figure 2D), ganglion cells (RGC5) (Figure 2A),ajp.amjpathol.org - The American Journal of Pathology
Figure 1 PGC-1a expression in the retina and during retinal devel-
opment. A: RNA from the indicated adult murine tissues was extracted and
subjected to RT-qPCR for PGC-1a. BeD: RNA from retinas of WT mice at age
postnatal day 1 (P1) to P17 were harvested and subjected to RT-qPCR. The
expression levels of PGC-1a (B) and its downstream target genes, CYCS and
MCAD (C), were increased with development with a surge from P3 to P7.
The developmental expression curve of PGC-1a also correlated with VEGFA,
PDGFB, and ANG2 expression during the early stage of vascular outgrowth
(up to P7). However, high PGC-1a expression is maintained during the
later stage of retinal development, whereas VEGFA expression is repressed
(D). *P < 0.05 versus P1. E: In situ hybridization for PGC-1a in P7.5 and
adult retina. Scale bar Z 50 mm.
PGC-1a and Retinal AngiogenesisPR (661W) (Figure 2B), and retinal pigment epithelial cells
(ARPE-19) (Figure 2C). Importantly, PGC-1a also efﬁciently
induced the expression of VEGFA in the same cells (Figure 2,
AeD). Multiple retinal cell types, including astrocytes,
ganglion cells, and RPE cells, have been shown to express
VEGFunder normal and pathological conditions.27However,The American Journal of Pathology - ajp.amjpathol.orgMüller cells are thought to be the main source of VEGFA in
the inner retina in response to hypoxia.28 We, therefore,
focused our attention on this cell type. MIO-M1 cell lines
stably expressing PGC-1a, versus empty control, were
generated by retroviral infection. PGC-1a protein expression
was increased approximately twofold (Figure 2E, inset). This
moderate induction of PGC-1a efﬁciently induced Cox5b
(Figure 2E). The cells were then placed in low-serum
medium, with and without hypoxia, to mimic as much as
possible the ischemic environment of the retina. PGC-1a
overexpression signiﬁcantly augmented the hypoxic induc-
tion of both VEGFA expression (Figure 2F) and secretion
(Figure 2G) in these cells. Conversely, inhibition of PGC-1a
by small hairpin RNA (shPGC-1a) in MIO-M1 cells signiﬁ-
cantly suppressed normal and hypoxia-induced VEGFA
expression (Figure 2H). PGC-1a thus regulates VEGFA
expression in a number of retinal cell types, including Müller
cells, in both normoxic and hypoxic conditions.
Vascular Development Is Abnormal in the Retinas of
Mice Lacking PGC-1a
The signiﬁcant up-regulation of PGC-1a expression during
retinal postnatal development and its effect on VEGFA
expression in various retinal cells suggest that PGC-1a may
play an important role during retinal vascular outgrowth. To
test this, retinal ﬂat mounts were obtained from P4 PGC-
1aedeﬁcient mice, versus their littermate wild-type (WT)
controls, and stained with the endothelial cell marker isolectin
B4. PGC-1a/ mice have been previously described,17 but
the effects of PGC-1a deﬁciency on the retinal vasculature
have not been reported. As shown in Figure 3, PGC-1a/
mice display a signiﬁcant inhibition of the superﬁcial vascular
plexus outgrowth, as evidenced by a reduced vascular radius
and area. This inhibitionwas associatedwith decreased number
of tip cells at the vascular leading front and a moderate, but
signiﬁcant, reduction of capillary density (Figure 3).
VEGFA is also important for arterial speciﬁcation of
retinal vessels.29 We therefore characterized the vascular
remodeling of PGC-1a/ by co-staining P13.5 ﬂat-
mounted retinas with isolectin B4 and smooth-muscle
actin, a marker for arterialized vessels (Figure 4A). At this
stage, the retinal vascular network is matured into well-
deﬁned arterioles, venules, and capillaries. Arterioles and
venules sprouting from the optic disk can be morphologi-
cally distinguished by their lumen size (larger in venules),
the presence of a capillary-free zone around the arterioles,
and the extent of smooth muscle cell coverage (stronger on
arterioles). Although WT animals displayed an average of
ﬁve main arteries and vein pairs sprouting from the optic
disk, a signiﬁcant reduction of the number of major vessels
pairs was observed in 27% of the PGC-1a/ animals
(Figure 4B). However, each pair maintained a proper
arterialevenous speciﬁcation. This phenotype was not asso-
ciated with abnormal astrocyte network organization (not
shown) or altered smooth muscle cell coverage. Interestingly,259
Figure 2 PGC-1a regulates VEGFA in retinal cells. RGC5 (A), 661W (B), ARPE-19 (C), and MIO-M1 (D) were infected with adenovirus expressing mouse
PGC-1a or GFP (as negative control). Forty-eight hours postinfection, RNA was isolated and gene expression measured by qPCR. VEGFA was up-regulated two-
to threefold in all cells. MIO-M1 were infected with retrovirus carrying vacant or mouse PGC-1a plasmids. PGC-1a expression at the protein level was elevated
with induction of its target genes (E). PGC-1aedependent up-regulation (F) and secretion (G) of VEGF in MIO-M1 cells is enhanced by hypoxia. PGC-1a
knockdown by shRNA inhibits VEGFA expression in normoxic and hypoxic conditions (H). *P < 0.05.
Saint-Geniez et althe vascular density of the P13.5 PGC-1a/ retinas appeared
normal, in contrast to P4.5 (Figure 3), suggesting that PGC-1a
deﬁciency delays vascular outgrowth, but does not reduce
ﬁnal vascular density or disrupt arterialevenous differentia-
tion. Together, these results indicate that PGC-1a contributes
to normal vascularization of the developing retina.
Despite these vascular anomalies observed during early
retinal development, the ocular structures and retinal layers
appeared otherwise normal in adult PGC-1a/mice, as seen
by H&Eestained sections (Figure 5, A and B). SD-OCT
imaging through the optic disk revealed also a normal
retinal conﬁguration (Figure 5C). Quantiﬁcation of the ONL
thickness conﬁrmed the absence of obvious degenerative
processes in adult PGC-1a/ mice (Figure 5D).
PGC-1a/ Mice Are Protected Against ROP in the OIR
Model
ROP is marked by excess neovascularization in response to
tissue ischemia. In light of the synergetic effect of PGC-1a
overexpression and hypoxia observed on VEGFA levels in
MIO-M1 cells, we reasoned that PGC-1a deﬁciency may
blunt the excess neovascularization that occurs during ROP.
To test this, the murine OIR model that recapitulates some of
the key features of ROP was used. In this model, 7-day-old
pups are placed with their mother in a hyperoxic chamber
(75% O2), where excess tissue oxygenation blunts the
hypoxic drive for developmental angiogenesis. On day 12,
the pups are returned to ambient air (21% O2), where the now
blunted vascular trees can no longer sustain tissue oxygen-
ation. Retinal ischemia ensues, leading to disorganized
angiogenesis and pathogenic neovascularization (Figure 6A).260We have shown previously that PGC-1a expression is
increased in skeletal muscle cells by ischemia-like condi-
tions.11 To test whether this is also the case in retinas sub-
jected to OIR, we examined the expression of PGC-1a in
retinas isolated from P12 to P17 mice exposed to OIR.
When measured in whole retinas, PGC-1a expression
appeared unchanged either by the hyperoxic treatment
(P12, Figure 6B) or during the hypoxic phase of the model
(P12 þ 6 hours to P17, Figure 6B). By contrast, VEGFA
was strongly down-regulated at P12 and then rapidly and
signiﬁcantly induced by the relatively hypoxic retina
(Figure 6B). We hypothesized, however, that PGC-1a may
be regulated differently in different retinal layers. Laser-
captured retinal layers followed by qPCR revealed that
PGC1a is expressed quite differently in the retinal layers.
The strongest expression of PGC1a is detected in the
photoreceptor outer nuclear layer (ONL), followed by the
INL, whereas the GCL expresses a much lower basal level
of PGC-1a (Figure 6D). The effects of OIR on PGC-1a
expression were remarkably layer speciﬁc. PGC1a was
strikingly induced in the INL (by over 190-fold), whereas it
was reduced about 60% in the ONL, and slightly (but not
signiﬁcantly) induced in the GCL (Figure 6D). When inte-
grated over the entire retina (Figure 6B), the strong
expression of PGC-1a in the ONL and its repression by OIR
thus completely masked the dramatic induction of PGC-1a
in the INL (Figure 6D). The INL contains the Müller cells,
the major source of VEGF during OIR.28 These data thus
indicate that PGC-1a is likely potently induced in Müller
cells by the relative ischemia induced by the OIR model.
The data above also strongly suggest that PGC-1a up-
regulation could be involved in the pathological induction ofajp.amjpathol.org - The American Journal of Pathology
Figure 3 Delayed retinal vascular development
and decreased capillary density in PGC-1a/mice.
Developmental retinal vessels outgrowth was eval-
uated at P4 on isolectin-B4 (green) and/or collagen
IV (red) stained flat-mounts (A) and quantified (B).
PGC-1a/ pups showed reduced vascular radius
(red arrows) and area compared to WT littermates
(A and B). High-magnification micrographs of the
vascular front revealed a decreased number of tip
cells (asterisks) in PGC-1a/ compared to WT (A).
Vascular density was quantified on collagen
IVestained P4 retina flat-mounts and revealed
a significant decrease of capillary density in
PGC-1a/ mice (nZ 5 to 7). *P < 0.05.
PGC-1a and Retinal AngiogenesisVEGFA and vessel proliferation during the OIR model of
ROP. Therefore, we next analyzed the effect of PGC1a
deﬁciency in the OIR model. As shown in Figure 7A, and
quantiﬁed in Figure 7B, pathological neovascularization
covers approximately 11% of the area of ﬂat mounts of WT
P17 mice that have undergone OIR. By contrast, only about
7% of the area of retinas from OIR PGC-1a/ mice haveFigure 4 Reduced number of main arteries and veins in PGC-1a/
mice. A: Flat-mounted retinas of WT and PGC-1a knockout littermates at
P13.5 were costained with isolectin B4 (green) and smooth-muscle actin
(red) to differentiate veins (v) and arteries (a). The number of main
arteries and veins was reduced in PGC-1a/ (B) (mean  SD, nZ 7 to 11)
*P < 0.05.
The American Journal of Pathology - ajp.amjpathol.orgsigns of pathological angiogenesis (P < 0.01), a reduction
of about 36%. Inhibition of PGC-1a is thus protective in the
OIR model of ROP.
Pathological angiogenesis in the OIR model is triggered by
hypoxia,which is proportional to the avascular area created by
the hyperoxic treatment. To test whether reduced angiogen-
esis in the PGC-1a/ OIR mice reﬂects a decreased area at
risk after the hyperoxic treatment, a separate cohort of mice
was sacriﬁced at P12, the end of the hyperoxic treatment. As
shown in Figure 7, C and D, the avascular area at P12 was
similar between PGC-1aþ/þ and PGC-1a/ animals. The
reduced pathological angiogenesis observed in PGC-1a/
mice in theOIRmodel (Figure 7,A andB) thus does not reﬂect
differences in avascular area at the end of the hyperoxic
treatment, and instead, most likely reﬂects decreased expres-
sion of VEGFA in response to the relative tissue ischemia
after withdrawal from hyperoxia. To test this, total RNA was
prepared from P17 retinas of PGC-1a/ and WT mice that
had undergone the OIR model. As shown in Figure 7E,
the expression of VEGFA was signiﬁcantly reduced in
PGC-1a/ retinas. Together, these data show that deletion of
PGC-1a protects against pathological neovascularization in
the OIR model, likely via reduced expression of VEGFA.Discussion
We show here that PGC-1a regulates normal and patho-
logical angiogenesis in the retina. Absence of PGC-1a in
knockout mice leads to defects in normal vascular261
Figure 6 Region-specific regulation of PGC-1a expression during OIR.
A: Schematic representation of the OIR model. B: qPCR quantification of
PGC-1a and VEGFA mRNA in total retinas from P12 to P17 in control (white
bars) and OIR (black bars) WT mice. C: Representative pictures of retinal
sections before (Pre LCM) and after (Post LCM) laser capture microdis-
section. D: mRNA quantification by qPCR from laser-captured ONL, INL, and
GCL of P17 control and OIR retinas (log y axis). Results are expressed as RE
(relative expression) normalized to housekeeping genes (mean  SEM,
n Z 3 to 4). *P < 0.05, **P < 0.01, and ***P < 0.001.
Figure 5 Normal ocular and retinal structures in PGC-1a/ mice. A
and B: H&E-stained sagittal ocular sections from 8-week-old PGC-1aþ/þ
(WT) and PGC-1a/ mice. A: Low magnification showing normal ocular
structures; scale bars Z 500 mm. B: Higher magnification showing no
abnormal retinal organization or layers thickness in PGC-1a/ mice; scale
barsZ 50 mm. C: Representative pictograms of SD-OCT recordings from WT
and PGC-1a/ mice, the ONL is indicated by double-ended arrows. Scale
bars Z 100 mm. D: ONL thickness from OCT recordings were quantified
every 100 mm from the optic nerve head (OD) (mean  SD, n Z 3 to 6).
GCL, ganglion cell layer; INL, inner nuclear layer; IS, inner segment; ONL,
outer nuclear layer; OS, outer segment.
Saint-Geniez et aloutgrowth, while at the same time diminishing excessive
pathological angiogenesis in the OIR model.
We show that PGC-1a regulates VEGFA in a number of
retinal cell types in vitro. It is likely that the predominant
effect of PGC-1a on retinal neovascularization is mediated in
Müller cells, which are thought to be the main source of
VEGFA30 and a major contributor to hypoxia-induced262vascular leakage and neovascularization.31 Consistent with
this, hypoxic conditions enhanced PGC1a-dependent
VEGFA up-regulation in Müller cells (Figure 2). Other cells
could of course also be at play. Retinal neovascularization is
regulated by complex interactions between vascular, glial,
and neuronal cells.32 PGC-1a is highly expressed inajp.amjpathol.org - The American Journal of Pathology
Figure 7 PGC-1a/ mice are protected
against OIR. Oxygen-induced retinopathy (OIR)
was induced by exposing PGC-1aþ/þ (WT) and
PGC-1a/ mouse pups to 75% oxygen from P7 to
P12. A and B: At P17, retinas were harvested and
stained with isolectin-B4. The vaso-obliterated
areas (yellow outline) and neovascular areas
(marked in white) were quantified using Photo-
shop CS4 software. Loss of PGC-1a did not affect
the avascular zone but significantly reduced the
neovascular area (nZ 7 to 9). **P < 0.01. C and
D: Representative pictograms (C) and quantifica-
tion (D) of the central vaso-obliteration induced
by hyperoxia at P12 (n Z 7 to 12). ns, no
statistical difference. E: qPCR analysis of total
retina mRNA isolated from P17 animals exposed to
OIR model revealed a significant reduction in
Cox5b and VEGFA expression in PGC-1a/ mice
compared to PGC-1aþ/þ (n Z 4). *P < 0.05,
***P < 0.001.
PGC-1a and Retinal Angiogenesisdeveloping PR (Figure 1) and was recently shown to be
involved in PR susceptibility to light damage.16 Even though
the PR do not appear to be a major source of proangiogenic
molecules even under severe hypoxia, the hypoxic state of
the PR can affect VEGFA expression and the subsequent
angiogenic response.33 However, since PGC-1a deﬁciency
does not cause retinal degeneration (Figure 5 and Egger
et al16), it seems unlikely that PGC-1aedependent modula-
tion of PR metabolism drives the reduced oxygen-dependent
neovascularization that we observed. PGC-1a could also be
involved in the homeostasis of endothelial cells.34 However,
PGC-1a expression in endothelial cells is extremely low
when compared to other cell types and, in particular, to
Müller cells (Supplemental Figure S2), suggesting that the
role of PGC-1a is likely much greater inMüller cells. Finally,
it is formally possible that some aspect of the phenotype
observed here reﬂects alterations in systemic metabolism in
the PGC-1a/ mice. The simplest interpretation of our
ﬁndings, however, is that the predominant effect of PGC-1a
is mediated in Müller cells, which are thought to be the
strongest secretors of VEGFA.30 Precise characterization of
function of PGC-1a in each cell type will require cell-speciﬁc
deletion with available ﬂoxed alleles of PGC-1a.
Angiogenesis in the retina, in particular in response to
physiological and pathological hypoxia has been thought to
be mediated primarily by the HIF-1 pathway, even though
evidence suggests that other pathways must exist.10 We
have shown previously that the induction of VEGFA and
angiogenic factors by PGC-1a in skeletal muscle isThe American Journal of Pathology - ajp.amjpathol.orgindependent of HIF-1a, occurring instead by coactivation of
the orphan nuclear receptor estrogen-related receptor
a (ERRa).11 The data presented here demonstrate that this
pathway is also likely at play in the retina. Interestingly, we
did not observe in PGC-1aedeﬁcient mice any changes in
the extent of oxygen-induced vaso-obliteration in the OIR
model, suggesting that, contrary to what occurs with HIF-1
proteins,35 PGC-1a is not involved in the maintenance of
the trophic factors that prevent microvascular obliteration. It
will be of interest to study retinal development and response
to OIR in ERRa/ mice. It will also ultimately be of
interest to attempt to intervene pharmacologically in this
novel pathway. Screens to identify small molecules that
modulate PGC-1a have yielded some results, for example,
but remain in the early stages.36
Some aspects of the phenotypes we observed in unchal-
lenged PGC-1a/ mice were incompletely penetrant (eg,
Figure 4). Thismay reﬂect effects of variable genetic modiﬁers
and/or variable compensation by other pathways. PGC-1b, for
example, regulates many of the same pathways as PGC-1a,
including angiogenesis in skeletal muscle.37 We did not
observe compensatory up-regulation of PGC-1b mRNA in
PGC-1a/mice, but compensation may have occurred at the
posttranscriptional level. It will be of interest, therefore, to
evaluate deletion of both PGC-1a and b simultaneously. This
will require conditional deletion in the appropriate cell type,
since PGC-1a/b doubly deleted mice die at birth.38
The PGC-1aeregulated pathway in the eye likely
provides an important node for regulation by multiple263
Saint-Geniez et alphysiological cues. Hypoxia is not the only challenge that
ischemic tissues face. Insufﬁcient blood ﬂow also leads to
deprivation of nutrients, pH changes, dramatic changes in
intermediate metabolism and cellular redox state, and
accumulation of numerous extracellular molecules. The role
that these metabolic events play in regulating angiogenesis
is not well understood. For example, Sapieha et al39 recently
showed that the hypoxic retina accumulates extracellular
succinate, which directly stimulates ganglion cells to secrete
VEGFA and other angiogenic factors independently from
the HIF pathway. Thus, the complex metabolic events that
occur during ischemia are clearly linked to the angiogenic
response, but the mechanisms involved remain incompletely
resolved. PGC-1a is extensively regulated, both at the
transcriptional and posttranslational levels, by upstream
signaling cascades including cAMP, mitogen-activated
protein kinase, and powerful metabolic sensors such as
AMP-activated protein kinase and sirtuin.14 PGC-1a thus
integrates multiple metabolic signals in addition to hypoxia,
and is in an ideal position to link those signals to angio-
genesis in the eye.
In summary, we show here that PGC-1a regulates
VEGFA and angiogenesis in the retina under both physio-
logical and pathophysiological conditions. Further study of
this novel pathway may lead to new insight and approaches
to treating a variety of retinal pathologies marked by inap-
propriate and deranged neovascularization, including ROP,
but also “wet” aged-related macular degeneration and dia-
betic retinopathy.
Acknowledgments
We thank Drs. Andrea Giani and Aristomenis Thanos
(Massachusetts Eye and Ear Inﬁrmary, Boston) for their
assistance in SD-OCT image acquisition.
Supplemental Data
Supplemental material for this article can be found at http://
dx.doi.org/10.1016/j.ajpath.2012.09.003.References
1. Yu DY, Cringle SJ: Oxygen distribution and consumption within the
retina in vascularised and avascular retinas and in animal models of
retinal disease. Prog Retin Eye Res 2001, 20:175e208
2. Saint-Geniez M, D’Amore PA: Development and pathology of the
hyaloid, choroidal and retinal vasculature. Int J Dev Biol 2004, 48:
1045e1058
3. Engerman RL, Pfaffenbach D, Davis MD: Cell turnover of capillaries.
Lab Invest 1967, 17:738e743
4. Phelps DL: Retinopathy of prematurity: an estimate of vision loss in
the United Statese1979. Pediatrics 1981, 67:924e925
5. Sapieha P, Joyal JS, Rivera JC, Kermorvant-Duchemin E, Sennlaub F,
Hardy P, Lachapelle P, Chemtob S: Retinopathy of prematurity:
understanding ischemic retinal vasculopathies at an extreme of life.
J Clin Invest 2012, 120:3022e30322646. Alon T, Hemo I, Itin A, Pe’er J, Stone J, Keshet S: Vascular endo-
thelial growth factor acts as a survival factor for newly formed retinal
vessels and has implications for retinopathy of prematurity. Nat Med
1995, 1:1024e1028
7. Chen J, Stahl A, Hellstrom A, Smith LE: Current update on retinop-
athy of prematurity: screening and treatment. Curr Opin Pediatr 2011,
23:173e178
8. Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Coopera-
tive Group: Efﬁcacy of intravitreal bevacizumab for stage 3þ reti-
nopathy of prematurity. N Engl J Med 2011, 364:603e615
9. Arjamaa O, Nikinmaa M: Oxygen-dependent diseases in the retina:
role of hypoxia-inducible factors. Exp Eye Res 2006, 83:473e483
10. Vinores SA, Xiao WH, Aslam S, Shen J, Oshima Y, Nambu H, Liu H,
Carmeliet P, Campochiaro PA: Implication of the hypoxia response
element of the Vegf promoter in mouse models of retinal and choroidal
neovascularization, but not retinal vascular development. J Cell
Physiol 2006, 206:749e758
11. Arany Z, Foo SY, Ma Y, Ruas JL, Bommi-Reddy A, Girnun G,
Cooper M, Laznik D, Chinsomboon J, Rangwala SM, Baek KH,
Rosenzweig A, Spiegelman BM: HIF-independent regulation of VEGF
and angiogenesis by the transcriptional coactivator PGC-1alpha.
Nature 2008, 451:1008e1012
12. Kelly DP, Scarpulla RC: Transcriptional regulatory circuits control-
ling mitochondrial biogenesis and function. Genes Dev 2004, 18:
357e368
13. Lin J, Handschin C, Spiegelman BM: Metabolic control through the
PGC-1 family of transcription coactivators. Cell Metab 2005, 1:
361e370
14. Handschin C, Spiegelman BM: Peroxisome proliferator-activated
receptor gamma coactivator 1 coactivators, energy homeostasis, and
metabolism. Endocr Rev 2006, 27:728e735
15. Arany Z: PGC-1 coactivators and skeletal muscle adaptations in health
and disease. Curr Opin Genet Dev 2008, 18:426e434
16. Egger A, Samardzija M, Sothilingam V, Tanimoto N, Lange C,
Salatino S, Fang L, Garcia-Garrido M, Beck S, Okoniewski MJ,
Neutzner A, Seeliger MW, Grimm C, Handschin C: PGC-1alpha
determines light damage susceptibility of the murine retina. PLoS One
2012, 7:e31272
17. Lin J, Wu PH, Tarr PT, Lindenberg KS, St-Pierre J, Zhang CY,
Mootha VK, Jager S, Vianna CR, Reznick RM, Cui L, Manieri M,
Donovan MX, Wu Z, Cooper MP, Fan MC, Rohas LM, Zavacki AM,
Cinti S, Shulman GI, Lowell BB, Krainc D, Spiegelman BM: Defects
in adaptive energy metabolism with CNS-linked hyperactivity in
PGC-1alpha null mice. Cell 2004, 119:121e135
18. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D’Amato R,
Sullivan R, D’Amore PA: Oxygen-induced retinopathy in the mouse.
Invest Ophthalmol Vis Sci 1994, 35:101e111
19. Vega RB, Huss JM, Kelly DP: The coactivator PGC-1 cooperates with
peroxisome proliferator-activated receptor alpha in transcriptional
control of nuclear genes encoding mitochondrial fatty acid oxidation
enzymes. Mol Cell Biol 2000, 20:1868e1876
20. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM:
A cold-inducible coactivator of nuclear receptors linked to adaptive
thermogenesis. Cell 1998, 92:829e839
21. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N,
De Paepe A, Speleman F: Accurate normalization of real-time quan-
titative RT-PCR data by geometric averaging of multiple internal
control genes. Genome Biol 2002, 3:RESEARCH0034
22. Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E,
Kurihara T, Darland DC, Young MJ, D’Amore PA: Endogenous
VEGF is required for visual function: evidence for a survival role on
Müller cells and photoreceptors. PLoS ONE 2008, 3:e3554
23. Connor KM, Krah NM, Dennison RJ, Aderman CM, Chen J,
Guerin KI, Sapieha P, Stahl A, Willett KL, Smith LE: Quantiﬁcation of
oxygen-induced retinopathy in the mouse: a model of vessel loss,
vessel regrowth and pathological angiogenesis. Nat Protoc 2009, 4:
1565e1573ajp.amjpathol.org - The American Journal of Pathology
PGC-1a and Retinal Angiogenesis24. Saint-Geniez M, Argence CB, Knibiehler B, Audigier Y: The msr/apj
gene encoding the apelin receptor is an early and speciﬁc marker of
the venous phenotype in the retinal vasculature. Gene Expr Patterns
2003, 3:467e472
25. Fruttiger M: Development of the retinal vasculature. Angiogenesis
2007, 10:77e88
26. Chinsomboon J, Ruas J, Gupta RK, Thom R, Shoag J, Rowe GC,
Sawada N, Raghuram S, Arany Z: The transcriptional coactivator
PGC-1a mediates exercise-induced angiogenesis in skeletal muscle.
Proc Natl Acad Sci U S A 2009, 106:21401e21406
27. Gariano RF, Gardner TW: Retinal angiogenesis in development and
disease. Nature 2005, 438:960e966
28. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE: Vascular
endothelial growth factor/vascular permeability factor expression in
a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A
1995, 92:905e909
29. Stalmans I, Ng YS, Rohan R, Fruttiger M, Bouche A, Yuce A,
Fujisawa H, Hermans B, Shani M, Jansen S, Hicklin D, Anderson DJ,
Gardiner T, Hammes HP, Moons L, Dewerchin M, Collen D,
Carmeliet P, D’Amore PA: Arteriolar and venular patterning in retinas
of mice selectively expressing VEGF isoforms. J Clin Invest 2002,
109:327e336
30. Stone J, Itin A, Alon T, Pe’er J, Gnessin H, Chan-Ling T, Keshet E:
Development of retinal vasculature is mediated by hypoxia-induced
vascular endothelial growth factor (VEGF) expression by neuroglia.
J Neurosci 1995, 15:4738e4747
31. Bai Y, Ma JX, Guo J, Wang J, Zhu M, Chen Y, Le YZ: Muller cell-
derived VEGF is a signiﬁcant contributor to retinal neovascularization.
J Pathol 2009, 219:446e454The American Journal of Pathology - ajp.amjpathol.org32. Vessey KA, Wilkinson-Berka JL, Fletcher EL: Characterization of
retinal function and glial cell response in a mouse model of oxygen-
induced retinopathy. J Comp Neurol 2011, 519:506e527
33. Lahdenranta J, Pasqualini R, Schlingemann RO, Hagedorn M,
Stallcup WB, Bucana CD, Sidman RL, Arap W: An anti-angiogenic
state in mice and humans with retinal photoreceptor cell degenera-
tion. Proc Natl Acad Sci U S A 2001, 98:10368e10373
34. Valle I, Alvarez-Barrientos A, Arza E, Lamas S, Monsalve M: PGC-
1alpha regulates the mitochondrial antioxidant defense system in
vascular endothelial cells. Cardiovasc Res 2005, 66:562e573
35. Duan LJ, Takeda K, Fong GH: Prolyl hydroxylase domain protein 2
(PHD2) mediates oxygen-induced retinopathy in neonatal mice. Am J
Pathol 2011, 178:1881e1890
36. Arany Z, Wagner BK, Ma Y, Chinsomboon J, Laznik D,
Spiegelman BM: Gene expression-based screening identiﬁes micro-
tubule inhibitors as inducers of PGC-1alpha and oxidative phosphor-
ylation. Proc Natl Acad Sci U S A 2008, 105:4721e4726
37. RoweGC, JangC, Patten IS, Arany Z: PGC-1b regulates angiogenesis in
skeletal muscle. Am J Physiol Endocrinol Metab 2011, 301:E155eE163
38. Lai L, Leone TC, Zechner C, Schaeffer PJ, Kelly SM, Flanagan DP,
Medeiros DM, Kovacs A, Kelly DP: Transcriptional coactivators
PGC-1alpha and PGC-lbeta control overlapping programs required
for perinatal maturation of the heart. Genes Dev 2008, 22:1948e1961
39. Sapieha P, Sirinyan M, Hamel D, Zaniolo K, Joyal JS, Cho JH,
Honore JC, Kermorvant-Duchemin E, Varma DR, Tremblay S,
Leduc M, Rihakova L, Hardy P, Klein WH, Mu X, Mamer O,
Lachapelle P, Di Polo A, Beausejour C, Andelﬁnger G, Mitchell G,
Sennlaub F, Chemtob S: The succinate receptor GPR91 in neurons has
a major role in retinal angiogenesis. Nat Med 2008, 14:1067e1076265
